Grail (NASDAQ:GRAL) stock has been highly volatile in 2026, and that trend looks set to continue next year as well. Management expects its multi-cancer early detection (MCED) test, Galleri, to be approved in the first quarter of 2027, but that’s only part of the story. Here’s what investors need to know and where the stock could be heading next year.
Grail’s ups and downs in 2026
The company finalized its pre-market approval submission for Galleri in late January, only to follow up with disappointing top-line results from its landmark three-year trial of Galleri with England’s National Health Service (NHS). The trial failed to meet its primary endpoint of a statistically significant reduction in the diagnosis of late-stage (III and IV) cancers in a population of 142,000.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a “Double Down” signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same “Total Conviction” signal is flashing for a company 1/100th the size of Nvidia. Continue »
The principle was that Galleri would detect cancers at an early stage (I and II), leading to less expensive, less intrusive, and more comfortable treatments and, ultimately, better patient outcomes. The trial’s overall failure obviously raised concerns about FDA approval and, more importantly, insurer coverage of the test. That’s the crash you can see in the stock in February.
Grail builds confidence
While the trial’s result was disappointing across the more than 50 cancers it tests for, it did demonstrate more compelling data across the 12 most deadly cancers (including anus, bladder, colorectal, head and neck, lung, ovary, pancreas, and stomach) that cause two-thirds of the deaths in the U.S.
As such, management continued to build the case that the Galleri test data were compelling enough to convince the FDA to approve the test and spur insurer adoption. It’s a case that management highlighted at the American Society of Clinical Oncology (ASCO) meeting at the end of May, when outlining both the NHS trial and a smaller 35,000-patient trial in the U.S. and Canada.
Image source: Getty Images.
The stock then soared in September after an FDA panel voted in favor of Galleri’s safety, effectiveness, and benefit, paving the way for FDA marketing approval in 2027.
The case for Galleri
The ultimate adoption of Galleri by insurers and medical bodies relies on a somewhat complex set of factors and criteria that don’t lend themselves to a binary assessment of trial results. For example, a medical insurer is highly likely to conduct a cost-benefit analysis, weighing the benefits of early detection against the test’s cost relative to alternative tests and the cost of false positives.